JP7216024B2 - 腫瘍細胞におけるＷｎｔシグナル伝達と拮抗するポリペプチド - Google Patents

腫瘍細胞におけるＷｎｔシグナル伝達と拮抗するポリペプチド Download PDF

Info

Publication number
JP7216024B2
JP7216024B2 JP2019565865A JP2019565865A JP7216024B2 JP 7216024 B2 JP7216024 B2 JP 7216024B2 JP 2019565865 A JP2019565865 A JP 2019565865A JP 2019565865 A JP2019565865 A JP 2019565865A JP 7216024 B2 JP7216024 B2 JP 7216024B2
Authority
JP
Japan
Prior art keywords
isvd
seq
lrp5
binding
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019565865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521478A5 (https=
JP2020521478A (ja
Inventor
ツィンツァラ，ヴィットリア
キューンケル，クラウス－ペーター
バイセ，マリー－アンジュ
クロミー，カレン
スターレンス，ステファニー
シュトルベ，ベアトリース
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59021278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7216024(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2020521478A publication Critical patent/JP2020521478A/ja
Publication of JP2020521478A5 publication Critical patent/JP2020521478A5/ja
Application granted granted Critical
Publication of JP7216024B2 publication Critical patent/JP7216024B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019565865A 2017-05-31 2018-05-30 腫瘍細胞におけるＷｎｔシグナル伝達と拮抗するポリペプチド Active JP7216024B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17173782 2017-05-31
EP17173782.8 2017-05-31
PCT/EP2018/064295 WO2018220080A1 (en) 2017-05-31 2018-05-30 Polypeptides antagonizing wnt signaling in tumor cells

Publications (3)

Publication Number Publication Date
JP2020521478A JP2020521478A (ja) 2020-07-27
JP2020521478A5 JP2020521478A5 (https=) 2021-07-26
JP7216024B2 true JP7216024B2 (ja) 2023-01-31

Family

ID=59021278

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019565865A Active JP7216024B2 (ja) 2017-05-31 2018-05-30 腫瘍細胞におけるＷｎｔシグナル伝達と拮抗するポリペプチド

Country Status (26)

Country Link
US (3) US11033636B2 (https=)
EP (1) EP3630816B1 (https=)
JP (1) JP7216024B2 (https=)
KR (1) KR102717656B1 (https=)
CN (1) CN110637030B (https=)
AR (1) AR111840A1 (https=)
AU (1) AU2018276409B2 (https=)
BR (1) BR112019022729A2 (https=)
CA (1) CA3060401A1 (https=)
CL (1) CL2019003419A1 (https=)
CO (1) CO2019012329A2 (https=)
EA (1) EA201992808A1 (https=)
ES (1) ES2979194T3 (https=)
HU (1) HUE067691T2 (https=)
IL (1) IL270854B2 (https=)
MA (1) MA48760A (https=)
MX (1) MX2019014331A (https=)
MY (1) MY200744A (https=)
NZ (1) NZ758031A (https=)
PE (1) PE20200610A1 (https=)
PH (1) PH12019502602A1 (https=)
PL (1) PL3630816T3 (https=)
TW (1) TWI887192B (https=)
UA (1) UA125761C2 (https=)
WO (1) WO2018220080A1 (https=)
ZA (1) ZA201906610B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3630816T3 (pl) * 2017-05-31 2024-08-05 Boehringer Ingelheim International Gmbh Polipeptydy antagonizujące sygnalizację wnt w komórkach nowotworowych
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
CN111655729B (zh) 2017-12-19 2023-10-20 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
JP7663501B2 (ja) * 2019-02-11 2025-04-16 スロゼン オペレーティング， インコーポレイテッド 眼障害におけるｗｎｔシグナル伝達の調節
TW202104258A (zh) * 2019-03-29 2021-02-01 德商百靈佳殷格翰國際股份有限公司 抗癌組合療法
KR20220078568A (ko) * 2019-08-14 2022-06-10 모드맵 테라퓨틱스 인코포레이티드 Lrp5 단백질에 결합하는 항체 및 사용 방법
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
KR102920873B1 (ko) * 2021-07-13 2026-02-02 인제대학교 산학협력단 NEURL 유전자, 이를 포함하는 발현벡터 또는 NEURL 단백질을 유효성분으로 포함하는 β-카테닌 과발현으로 인한 암질환 예방 또는 치료용 약학조성물
WO2023019137A1 (en) * 2021-08-10 2023-02-16 Heat Biologics, Inc. Generation and characterization of novel tim-4 binding agents
CN114702588B (zh) * 2022-04-27 2022-11-22 博际生物医药科技(杭州)有限公司 抗Nectin-4抗体和双特异性抗体
CN120424217B (zh) * 2025-04-30 2026-03-06 立凌生物制药(苏州)有限公司 靶向b细胞抗原和t细胞抗原的多特异性抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1998046743A1 (en) 1997-04-15 1998-10-22 The Wellcome Trust Limited As Trustee To The Wellcome Trust Novel ldl-receptor
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
IL158750A0 (en) 2001-05-17 2004-05-12 Genome Therapeutics Corp Reagents and methods for modulating dkk-mediated interactions
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
WO2004041867A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006122787A1 (en) 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
US20090220488A1 (en) * 2005-08-31 2009-09-03 Humphrey Gardner Evaluating and treating scleroderma
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
CN101965362A (zh) 2008-03-05 2011-02-02 埃博灵克斯股份有限公司 新型抗原结合二聚体-复合物及其制备方法和应用
EP2268668A1 (en) 2008-04-17 2011-01-05 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8716243B2 (en) 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
UY33253A (es) 2010-03-03 2011-09-30 Boehringer Ingelheim Int Polipéptidos de unión a a-beta
AR080795A1 (es) * 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
EP4234698A3 (en) * 2010-05-06 2023-11-08 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
JP2014506568A (ja) 2011-01-28 2014-03-17 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ Ｗｎｔ組成物およびその使用方法
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
DK2723769T4 (da) 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
SG2014010482A (en) 2011-08-17 2014-04-28 Glaxo Group Ltd Modified proteins and peptides
CN104039830A (zh) 2011-11-04 2014-09-10 诺华股份有限公司 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
EP2804629A1 (en) * 2012-01-18 2014-11-26 Genentech, Inc. Anti-lrp5 antibodies and methods of use
CN120535622A (zh) 2015-11-18 2025-08-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
KR102802241B1 (ko) * 2015-12-04 2025-05-07 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
PL3630816T3 (pl) * 2017-05-31 2024-08-05 Boehringer Ingelheim International Gmbh Polipeptydy antagonizujące sygnalizację wnt w komórkach nowotworowych
TW202104258A (zh) * 2019-03-29 2021-02-01 德商百靈佳殷格翰國際股份有限公司 抗癌組合療法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLoS One; 2011; 6 (8), e23537
PNAS, 2010; 107 (35), pp.15473-15478

Also Published As

Publication number Publication date
EP3630816B1 (en) 2024-03-20
MX2019014331A (es) 2020-01-27
ZA201906610B (en) 2025-12-17
IL270854B (en) 2022-10-01
PL3630816T3 (pl) 2024-08-05
EP3630816C0 (en) 2024-03-20
EP3630816A1 (en) 2020-04-08
CO2019012329A2 (es) 2020-01-17
CA3060401A1 (en) 2018-12-06
EA201992808A1 (ru) 2020-05-14
IL270854B2 (en) 2023-02-01
UA125761C2 (uk) 2022-06-01
CN110637030A (zh) 2019-12-31
AU2018276409A1 (en) 2019-10-31
AU2018276409B2 (en) 2025-02-27
KR20200011933A (ko) 2020-02-04
CN110637030B (zh) 2024-06-11
ES2979194T3 (es) 2024-09-24
NZ758031A (en) 2026-03-27
TWI887192B (zh) 2025-06-21
US20180344868A1 (en) 2018-12-06
KR102717656B1 (ko) 2024-10-14
US11033636B2 (en) 2021-06-15
TW201906858A (zh) 2019-02-16
MY200744A (en) 2024-01-13
HUE067691T2 (hu) 2024-11-28
JP2020521478A (ja) 2020-07-27
AR111840A1 (es) 2019-08-21
US12285493B2 (en) 2025-04-29
US20220362393A1 (en) 2022-11-17
CL2019003419A1 (es) 2020-03-27
PE20200610A1 (es) 2020-03-10
WO2018220080A1 (en) 2018-12-06
PH12019502602A1 (en) 2020-06-08
BR112019022729A2 (pt) 2020-05-19
US20250345448A1 (en) 2025-11-13
MA48760A (fr) 2020-04-08
IL270854A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US11952418B2 (en) Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
JP7216024B2 (ja) 腫瘍細胞におけるＷｎｔシグナル伝達と拮抗するポリペプチド
CA3006235C (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
HK40040630A (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
HK1255725B (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
EA046752B1 (ru) Полипептиды, препятствующие передаче wnt сигналов в опухолевых клетках
EA040170B1 (ru) БИПАРАТОПНЫЕ ПОЛИПЕПТИДЫ-АНТАГОНИСТЫ ПЕРЕДАЧИ СИГНАЛА Wnt В ОПУХОЛЕВЫХ КЛЕТКАХ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230119

R150 Certificate of patent or registration of utility model

Ref document number: 7216024

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250